ArticleMedical molecular morphology2019

Phosphorylated HER3 and FITC-labeled trastuzumab immunohistochemistry in patients with HER2-positive breast cancer treated with adjuvant trastuzumab.

Naoki Kanomata et al.PubMed ↗Publisher ↗

No numbers read from the abstract.